Exelixis, Inc. EXEL
Follow Exelixis free
Follow free
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Updated: 16 Sep 2026
Base analysis: 18 Jul 2026
The news check keeps the assessment current.
General analysis — not personal advice.
HOLD
Clear
Maintain current position; consider adding on weakness below 50 USD
Stable profitability and confirmed patent exclusivity for cabozantinib balance the delayed zanzalintinib launch and support a neutral stance.
Market sentiment
Neutral ↓
Trend: Declining
Sentiment remains neutral with ongoing uncertainty around pipeline timelines after the delay.
Risk assessment
Medium
Dilution:
Low
Profitable company with large buybacks
Jurisdiction:
Low
Operations primarily in the US
Execution:
Medium
Dependent on clinical results and FDA
HOLD is the call. Neutral is the market mood. Medium risk means some things can go wrong.
Latest change
- 6 Aug 2026 — Report issued August 5 showed revenue of USD 629M, driving lowered full-year guidance due to slower NET growth.
About the company
Exelixis is a biotech company focused on discovering and commercializing targeted cancer therapies. Its main product cabozantinib (CABOMETYX/COMETRIQ) generates strong revenues. The company has a growing pipeline led by zanzalintinib as the next potential growth driver.
Sector:
Oncology / cancer drugs
Type:
Biotech
Next report (Q3)
5 Nov 2026
Catalysts
3 Mar 2027
FDA decision zanzalintinib
High
Bull case
Strong profit generation and confirmed patent exclusivity for cabozantinib provide long-term support for the company.
Bear case
Delayed zanzalintinib launch and slower NET growth increase uncertainty around the growth trajectory.
Why this signal
Stable profitability and confirmed patent exclusivity for cabozantinib balance the delayed zanzalintinib launch and support a neutral stance.
Recent news
- FDA extended the review of zanzalintinib + atezolizumab by three months to PDUFA 3 March 2027 after updated safety and efficacy data were classified as a major amendment. The patent victory against MSN Laboratories secures cabozantinib exclusivity until at least 2030. A securities investigation has been initiated by Levi & Korsinsky.
Key figures
Revenue
Q2 2026
USD 629M
Revenue TTM
TTM
USD 1.2B
Net income
Q2 2026
USD 212M
Cash
Q2 2026
USD 1.4B
Exchange
NASDAQ
Type
Biotech
Sector
Oncology / cancer drugs
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.